Bio-Rad Laboratories in the news

Bio-Rad Laboratories develops, manufactures, and sells products for clinical diagnostics and life sciences.

Bio-Rad Laboratories, operating in the life sciences tools and diagnostics sector, is navigating a challenging market environment by focusing on clinical diagnostics and digital PCR, while managing research funding pressures and economic shifts.

Bio-Rad Laboratories' stock is sliding due to profit-taking, despite the company's strategic pivot toward higher-margin recurring revenue and strong financial position.

Bio-Rad Laboratories is strategically focusing on higher-margin, recurring consumables and reagents to mitigate funding swings and soft instrument demand, influencing its investment outlook.

Bio-Rad Laboratories' stock is experiencing volatility due to a cautious outlook, weak life science demand, and analyst forecast cuts.

Bio-Rad Laboratories develops, manufactures, and sells products and solutions for clinical diagnostics and life sciences.

Bio-Rad Laboratories' stock fell 5.2% on October 1, 2026, amid a sector-wide selloff impacting medical device and life sciences companies.

Bio-Rad Laboratories' stock has shown recent gains but is deemed 15% overvalued, with risks including weak instrument demand and changing reimbursement policies in China.

Bio-Rad Laboratories Inc. shares dropped 5.9% to $355.57, are considered overvalued based on a GF Score™ of 73/100, and show insider selling and mixed guru activity.

Bio-Rad Laboratories' revenue last year was 2.20 billion EUR, with Clinical Diagnostics as the top segment and the United States as the largest regional contributor, both showing a decline from the previous year.

Bio-Rad Laboratories develops, manufactures, and distributes life science research and clinical diagnostic products across two segments, serving diverse industries globally.

RBC Capital maintained an Outperform rating for Bio-Rad Laboratories Inc. following investor meetings that clarified the company's multi-year transformation strategy aiming for sales growth recovery and margin improvement by 2027.

Bio-Rad Laboratories delivered Q1 results within guidance, bolstered by digital PCR growth and the Stilla acquisition, but faced headwinds from Middle East conflict and constrained academic demand, leading to a revised 2026 outlook.

Bio-Rad Laboratories is discussing its Q1 performance, operational items, and strategic priorities at the Jefferies Global Healthcare Conference.

Bio-Rad Laboratories is leveraging a partnership with Biodesix for molecular residual disease monitoring, aiming to grow in high-value diagnostics amidst market challenges.

Bio-Rad Laboratories is pursuing growth through Digital PCR, strategic M&A, and operational restructuring to improve profitability and cash flow.

Bio-Rad Laboratories is leveraging a partnership with Biodesix for Molecular Residual Disease monitoring to boost its high-value molecular and clinical diagnostics portfolio amid growth and margin challenges.

Bio-Rad Laboratories is undergoing a multi-year transformation to achieve profitable growth by optimizing its portfolio, operations, and M&A strategy, focusing on existing products and efficient cost structures.

Biodesix is developing two distinct molecular residual disease monitoring programs with Bio-Rad and Thermo Fisher Scientific to detect circulating tumor DNA following cancer treatment.

Biodesix is progressing molecular residual disease testing programs with Bio-Rad and Thermo Fisher Scientific to detect cancer in blood samples.